Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer

Shots:

Under the terms of the agreement, Immutep & Merck KGaA will jointly fund the clinical trial (INSIGHT-005) whereas the Institute of Clinical Cancer Research will conduct the study as part of the INSIGHT platform that consists 5 arms from stratum A to E
The stratum E arm, clinical trial (INSIGHT-005) is expected to evaluate the safety & efficacy of efti + avelumab in patients (n=30) with metastatic urothelial cancer with the 1st patient expected to be enrolled & dosed in H1’23 & study to be held in Germany
Efti is a soluble LAG-3 candidate that is a first-in-class APC activator for the treatment of cancer. Additionally, efti was previously evaluated in the clinical trial (INSIGHT-004) in solid tumor patients

Ref: Globenewswire | Image: Immutep